shares of aquestive therapeutics inc aqst tumbled 284 in premarket trading after the company said monday that the food and drug administration is delaying the review of its stillinvestigational seizure treatment the regulator was expected to announce its decision about whether to approve the therapy by dec 23 the fda said in the notice that it is currently unable to provide an estimate of the timing of an expected action the fda is not requiring any additional information from aquestive at this time the companys stock gained 162 so far this year while the broader sp 500 spx is up 216